TerminatedNot Applicable

PK of Piperacillin/Tazobactam in Adults Undergoing ECMO

Stopped: Lack or eligible patients.

United States2 participantsStarted 2019-01-01

Plain-language summary

This study is designed to provide preliminary data to determine if concentrations of piperacillin/tazobactam change in patients with severe respiratory failure receiving extracorporeal membrane oxygenation (ECMO). The investigators hypothesize that patients will have significant changes in concentration measurements, specifically an increased clearance rate and increased volume of distribution, during ECMO as compared to critically ill patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients 18 years of age or older * Initiated on VV ECMO for acute respiratory distress syndrome * Receiving piperacillin/tazobactam Exclusion Criteria: * Pregnancy * Massive blood transfusion (10 units or more of of PRBC) within a 24-hour period * Prisoners

What they're measuring

Change in clearance rate

Timeframe: Up to 2 days after the first dose of piperacillin/tazobactam

Change in volume of distribution

Timeframe: Up to 2 days after the first dose of piperacillin/tazobactam

Trial details

NCT IDNCT03467854

SponsorColumbia University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-09-24

View on ClinicalTrials.gov More Acute Respiratory Failure With Hypoxia trials